Teva Wins Defense Verdict in Paragard IUD Bellwether Trial

Teva Pharmaceuticals secured a defense verdict in the first U.S. jury trial arising from consolidated federal litigation alleging injuries linked to the Paragard copper intrauterine device (IUD). The Atlanta federal jury’s decision followed a two-week bellwether trial intended to test how jurors assess claims that Paragard can fracture during removal and that users and physicians were not adequately warned of that risk. With thousands of similar cases centralized in multidistrict litigation, the verdict offers an early data point on liability and causation theories that have driven the broader docket. The ruling also places increased attention on upcoming bellwether trials and on how courts address federal labeling standards and related preemption arguments.

The Bellwether Verdict and Its Role in the MDL

The jury in the Northern District of Georgia rejected plaintiff Pauline Rickard’s claim that Teva failed to warn about Paragard’s potential to break during removal. The case was selected as the first bellwether from a pool of more than 3,800 lawsuits asserting similar theories of injury, including allegations that fragments can remain in the body and require surgical intervention. Bellwether trials are not binding on other plaintiffs, but they are commonly used by litigants and courts to test evidentiary themes, assess witness credibility, and approximate how juries value contested injury and warning claims.

The defense verdict may influence how both sides evaluate settlement posture and trial strategy, but it does not resolve the merits of the remaining cases. Rickard alleged that she required multiple procedures following removal attempts, while Teva maintained that its labeling and physician-directed warnings were sufficient. The court is scheduled to proceed with additional bellwether trials in the coming months, which may further clarify how juries respond to competing accounts of device performance, clinical risk communication, and the proof needed to connect an alleged breakage event to specific injuries and damages.

Core Allegations: Breakage Risk, Removal Complications, and Warnings

Paragard is a non-hormonal, copper IUD intended to provide long-term contraception and is placed and removed by clinicians. The pending lawsuits generally allege that the device can break while in situ or during attempted removal, leaving components behind and creating a need for additional medical procedures. Plaintiffs contend that these complications may include pain, bleeding, uterine injury, and reproductive impacts, and that clearer warnings could have altered clinical decision-making, patient consent, or follow-up care. In many cases, the dispute centers on the frequency and foreseeability of breakage and on whether the risk was communicated in a manner consistent with applicable standards.

Regulatory and labeling issues have also been part of the public record surrounding the product. According to widely cited summaries in the litigation context, Paragard’s label was updated in 2024 to include language addressing breakage risk, and federal regulators have previously reviewed safety signals associated with user and clinician reports. In the MDL, such developments may be used by parties to frame notice, medical understanding over time, and the adequacy of risk disclosure, while courts may scrutinize how later label changes interact with arguments about what was feasible or required during earlier periods of distribution and use.

Teva’s Defenses: Product Ownership, Preemption, and Physician Warnings

Teva sold Paragard to CooperSurgical in 2017, and the litigation has distinguished between claims tied to periods of product ownership. In Rickard’s case, her claims against CooperSurgical were dismissed separately, leaving Teva to defend claims brought by individuals who received Paragard when Teva owned the product. Teva has argued that plaintiffs’ theories are preempted by federal law governing labeling and that the company adequately warned physicians about the possibility of breakage. These defenses place focus on the boundary between federal regulatory requirements and state-law failure-to-warn theories, including whether plaintiffs can show a viable path for additional warnings without conflicting with federal standards.

The defense team for Teva includes attorneys from Butler Snow, according to court filings. As the MDL advances, continued motion practice and trial rulings are likely to refine the admissibility of evidence concerning labeling history, adverse event reports, and causation narratives tied to individual removal procedures. With two more bellwether trials planned, future verdicts may help define which factual and scientific disputes are most determinative for jurors, and whether the parties can narrow issues sufficiently to evaluate global resolution frameworks without litigating thousands of cases to completion.